The company said, “On May 4, 2026, the U.S. Securities and Exchange Commission informed Agenus (AGEN) that it has concluded its investigation as to the Company and does not intend to recommend an enforcement action. Separately, on March 24, 2026, the U.S. District Court for the District of Massachusetts granted Agenus’s motion to dismiss the related putative securities class action in its entirety. The lead plaintiff has filed a Notice of Appeal to the U.S. Court of Appeals for the First Circuit. Additional information regarding both matters is included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- AGEN Earnings this Week: How Will it Perform?
- Agenus appoints BAP Pharma as global partner for BOT+BAL access programs
- Agenus reports Phase 2 results from BOT and BAL with agenT-797
- Agenus announces first patient enrolled in Phase 3 BATTMAN trial of BOT+BAL
- Agenus: Strengthening Bot/Bal Clinical Profile and Capital-Efficient Path to Registration Underpin Positive Rating
